Although, in most cancer types, IFNγ exerts strong anti-tumorigenic effects,9,10 several lines of evidence suggest that the increased production of IFNγ during TKI treatment might play a negative effect on the therapeutic response of CML patients. The gene discussed is IFNG; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.